Clinical trial
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT04278144
Study timeline
Study start (actual)2020-02-24Date precision: day
Registry last updated2025-09-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2-positive Solid Tumorsunresolved
HER2-positive Breast Cancerunresolved
HER2-positive Colorectal Cancerunresolved
HER2-positive Gastroesophageal Cancerunresolved
HER2-positive Endometrial Cancerunresolved
Interventions
BDC-1001DRUG
NivolumabDRUG · verified · RxNorm: nivolumab
Sponsors & collaborators
Bolt Biotherapeutics, Inc.lead sponsor
Bristol-Myers Squibbcollaborator
Mapped research locations
MadridMadrid, Spain2BarcelonaCatalonia, Spain2New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1ChicagoIllinois, United States1San AntonioTexas, United States1Washington D.C.District of Columbia, United States1Oklahoma CityOklahoma, United States1CharlotteNorth Carolina, United States1MarseilleFrance1BordeauxFrance1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04278144 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.